SEC Comment Letter for DRUGMAX INC (CIK 0000921878) — Sep 29, 2005

DRUGMAX INC (CIK 0000921878)
Date: Sept. 29, 2005 · CIK: 0000921878 · Accession: 0000000000-05-050393

View on Edgar

AI Filing Summary & Sentiment

Date

September 29, 2005

Author

Jeffrey Riedler

Form

UPLOAD

Company

DRUGMAX INC (CIK 0000921878)

Letter

Mail Stop 6010 September 29, 2005 DrugMax, Inc. 312 Farmington Avenue Farmington, CT 06032 Attn: Allison Kiene

Re: DrugMax, Inc. Preliminary information statement filed September 27, File No. 1-15445

Dear Ms. Kiene:

This is to advise you that we have monitored the subject filing solely with respect to the issue raised in the following comment.

We note that your discussion of an increase in the number of authorized shares of common stock of the company. Please expand the disclosure to state whether or not you have any plans, agreements, arrangements or understandings to issue any additional shares of common stock.

As appropriate, please amend your filing in response to this comment. If you disagree, we will consider your explanation as to why a comment is inapplicable or a revision is unnecessary. Please be as detailed as necessary in your explanation.

Any questions should be directed to Michael Reedich at (202) 551-3612.

Sincerely,
Jeffrey Riedler
Assistant Director

Show Raw Text

<DOCUMENT>
<TYPE>LETTER
<SEQUENCE>1
<FILENAME>filename1.txt
<TEXT>

Mail Stop 6010							September 29, 2005

DrugMax, Inc.
312 Farmington Avenue
Farmington, CT 06032
Attn: Allison Kiene

Re:	DrugMax, Inc.
       	Preliminary information statement filed September 27,
2005
       	File No. 1-15445

Dear Ms. Kiene:

	This is to advise you that we have monitored the subject
filing
solely with respect to the issue raised in the following comment.

We note that your discussion of an increase in the number of
authorized shares of common stock of the company.  Please expand
the
disclosure to state whether or not you have any plans, agreements,
arrangements or understandings to issue any additional shares of
common stock.

	As appropriate, please amend your filing in response to this
comment.  If you disagree, we will consider your explanation as to
why a comment is inapplicable or a revision is unnecessary.
Please
be as detailed as necessary in your explanation.

	Any questions should be directed to Michael Reedich at (202)
551-3612.

							Sincerely,

							Jeffrey Riedler
							Assistant Director

1

</TEXT>
</DOCUMENT>

SecProbe.io